Bavarian Nordic A S (BVNKF) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the Bavarian Nordic Q2 and a half year report for the six month period ended 30th of June, 2026 conference call. At this time, all participants are in a listen only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising Johannes Reiss. To answer your question, please press star one and one again. Please be advised that today's conference is being recorded. I will now like to hand the conference over to your speaker today, CEO Paul Chaplin. Please go ahead. Thank you and welcome everyone to our half year conference call. Today we've announced our Q2 results and before I go into them, and then hand over the call to Henrik Juuel, the CFO. Obviously we've announced tremendous results today, driven by very strong growth across the whole commercial portfolio. And before I get into those numbers, I just wanna say these sort of numbers don't happen by chance. It's an endorsement of our strategy, but more importantly, it's an endorsement of our employees and their hard work and dedication, but also our partners around the world and other healthcare professionals who work together with the Verenordic to really ensure that we improve the access to our life saving vaccines. So for the first half year, we've reported just over 3 billion kroner in revenue and an EBITDA margin of 35%. As I said, this really equates to a tremendous result. On travel health, we've seen a tremendous growth of 26% for the first six months. and actually 45% for the second quarter. And that's driven for the whole portfolio, but primarily driven by rabies and TBE, the first assets we ac...